RPI 4610
Alternative Names: Angiozyme; Cancer ribozyme therapyLatest Information Update: 25 Sep 2021
At a glance
- Originator Sirna Therapeutics
- Developer Chiron Corporation; Sirna Therapeutics
- Class Antineoplastics; Ribozymes
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Solid tumours
Most Recent Events
- 09 Aug 2004 Discontinued - Phase-II for Breast cancer in USA (SC)
- 09 Aug 2004 Discontinued - Phase-II for Colorectal cancer in USA (SC)
- 09 Aug 2004 Discontinued - Phase-II for Solid tumours in USA (SC)